Skip to main content
Dr. Lal Pathlabs Limited logo

Dr. Lal Pathlabs Limited — Investor Relations & Filings

Ticker · LALPATHLAB ISIN · INE600L01024 LEI · 984500E8E9CY102B9718 BSE.NS Human health and social work activities
Open in API
Filings indexed 1,098 across all filing types
Latest filing 2022-02-10 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS LALPATHLAB

About Dr. Lal Pathlabs Limited

https://www.lalpathlabs.com/

Dr. Lal Pathlabs Limited is a provider of diagnostic and related healthcare tests and services. The company offers a comprehensive range of clinical laboratory tests and profiles used for prediction, early detection, diagnostic screening, confirmation, and monitoring of diseases. Its service portfolio encompasses pathology, including biochemistry, hematology, clinical pathology, histopathology, and molecular diagnostics, as well as radiology services such as X-ray, ultrasound, and CT scans. The organization operates an extensive network of laboratories, patient service centers, and pick-up points, utilizing advanced automated systems and standardized processes. Key offerings include specialized wellness packages and home sample collection. The company maintains high quality standards through international and national accreditations, serving a diverse patient base and healthcare providers with a focus on accuracy and timely reporting.

Recent filings

Filing Released Lang Actions
Financial Result Updates
Interim / Quarterly Report Classification · 100% confidence The document is a communication from the company to stock exchanges reporting the approval of unaudited financial results for the quarter and nine months ended December 31, 2021. It includes the Independent Auditor's Review Report on these interim financial results, both consolidated and standalone, prepared under Indian Accounting Standard 34 for interim financial reporting. The document references Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to quarterly financial results. The presence of unaudited financial results for a period shorter than a full fiscal year and the auditor's review report confirms this is an Interim / Quarterly Report. The document length is over 10,000 characters and contains substantive financial data and analysis, not merely an announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR). 9M 2022
2022-02-10 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document is an invitation and intimation of a conference call scheduled for February 10, 2022, to discuss the Q3 and 9 months financial results for FY22 of Dr. Lal PathLabs Limited. It references the upcoming earnings announcement and provides details for investors and analysts to join the call. There are no actual financial statements or substantive financial data included in the document. The document is primarily an announcement of the conference call event related to earnings, not the earnings release itself or a transcript. Therefore, the document fits the category of a Call Transcript (CT) invitation or announcement. However, since it is only an invitation and not the transcript, the best fitting category is Call Transcript (CT) as it relates to the conference call content and format.
2022-02-04 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a notice from Dr. Lal PathLabs Limited informing the stock exchanges about a scheduled Board Meeting to consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2021. It references Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of events or information by listed entities. The document is short (1517 characters) and serves as an announcement of an upcoming board meeting and financial results approval, not the financial results report itself. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not contain actual financial data or detailed report content.
2022-02-02 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming no demat requests were received during the quarter ended December 31, 2021. It is a short letter addressed to stock exchanges and company secretary, providing regulatory compliance confirmation. It does not contain financial statements, management discussion, or detailed report data. The document length is only 2059 characters, indicating it is a brief regulatory compliance certificate rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2022-01-11 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a notice regarding the closure of the trading window in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. It informs the stock exchanges about the trading window closure period around the announcement of financial results for the quarter and nine months ending December 31, 2021. The document does not contain any financial data, detailed report, or results itself, but is an announcement related to trading restrictions. It is short (1108 characters) and serves as a regulatory notification rather than a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance and regulatory announcements that do not fit other specific categories.
2021-12-31 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice addressed to stock exchanges about the schedule of an analyst/institutional investor meeting. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The content is an intimation or announcement of a meeting schedule, not the meeting transcript or presentation itself. The document length is only 1598 characters, indicating it is a brief announcement rather than a detailed report or transcript. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-12-07 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.